fluidx
-
Fluidx Medical’s Embolic Demonstrates Novel Visibility Advantage
Fluidx Medical Reports Initial Research on First-of-its-Kind Embolic Agent with Intermediate Radiopacity
-
GPX Embolic Device Success in Challenging Tumor Case
Fluidx Medical’s Novel Embolic Device Demonstrates Repeated Success in Treating Complex Tumors
-
Fluidx Medical Technology Announces Series A Led by Multinational Strategic Investor
Novel Oncology Embolic Device financing supports prospective, clinical trials and market entry
-
Innovative Embolic Device Shows Promise for Interventional Oncology Drug Delivery
Fluidx Medical’s GPX Embolic Device Releases Initial Results for Oncology Drug Delivery
-
Fluidx Medical Technology’s Innovative Embolic Tumor Treating Device Highlighted in “BEST of GEST” Session at the Global Embolization Oncology Symposium Technologies (“GEST”) Conference
Fluidx Medical’s GPX™ Embolic Device Use for Tumor Treatments Chosen for “BEST of GEST” Embolization Program at the…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
